Navigation Links
Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
Date:8/16/2010

e="border:0px" alt="Click to view news release full screen">  

Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC

 

MONT-SAINT-GUIBERT, Belgium, August 16, 2010 /PRNewswire/ --

- Article Described a Landmark Process Generating Cardiac Precursor Cells to Rebuild Heart Tissue

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication(1).

The research, carried out at Mayo Clinic in Rochester, Minnesota, USA, and in collaboration with the Cardiovascular Center in Aalst, Belgium led to the development of Cardio3 BioSciences' technological platform designed to reprogram the patient's own stem cells to rebuild the heart.

In this ground-breaking work, researchers were able to identify a process involving a cocktail of growth factors to successfully reprogram mesenchymal (connective tissue) stem cells (MSCs) harvested from the bone marrow of heart failure patients into cardiac precursor cells.

Injected into an animal model of heart disease, these cardiac precursor cells improved heart function by repopulating scar tissue and generating new blood vessels, effectively eliminating the scar and rebuilding the heart with new functional human heart tissue. Treated animals demonstrated improved heart function and were cured from their heart failure.

In their editorial, Eduardo Marban, M.D., Ph.D., and Konstantinos Malliaras, M.D., of Cedars-Sinai Heart Institute, describe the
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
3. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
4. Signum Biosciences Names Braham Shroot as Chief Executive Officer
5. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
6. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
7. Ambit Biosciences Announces Transition in Company Leadership
8. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
9. Calithera Biosciences Closes $40 Million in Series A Financing
10. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
11. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
(Date:9/22/2014)... it is to stop bleeding, are very simple. They ... the physical environment around them, researchers at Emory and ... with greater stiffness by increasing their stickiness, the degree ... components of the clotting system, the researchers found. , ... in that they are able to sense the physical ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Platelets modulate clotting behavior by 'feeling' their surroundings 2
... Texas, Jan. 5, 2012  Healthpoint Biotherapeutics today announced that ... Robert Bancroft, Executive Vice President, Strategic and Commercial Development, ... products and its R&D pipeline at the upcoming J.P. ... January 9th, at 9:30 am (PST) at the Westin ...
... Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis company, today ... presentation at the 5 th Annual OneMedForum San ... Francisco, Calif., January 9-12, 2012. The company ... beginning at 10:00 a.m. Pacific Time.  The presentation will ...
... 5, 2012  ZyGEM Corp. Ltd., a developer and ... DNA and other nucleic acids, and the US ... today announced the signing of a Cooperative Research ... simplified sample processing solutions for biothreat agents.  The ...
Cached Biology Technology:WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 3
(Date:9/23/2014)... times more carbon than the atmosphere and small ... big effect on atmospheric greenhouse gas concentrations. A ... Change concludes that climate warming does not ... carbon storage, despite increases in ecosystem productivity. ... Research Ecologist Dr. Christian Giardina, with the agency,s ...
(Date:9/23/2014)... temperature on insects to predict how climate change will ... shows for the first time that insects, fear of ... fast they grow. , "In other words, it,s less ... that shape the growth, survival and distribution of insects." ... an Arctic postdoctoral researcher at Dartmouth. , The ...
(Date:9/23/2014)... Eureka Therapeutics, Inc. announced today that the Company has ... new funding will be used to expand the Company,s ... clinical development. New investor Yuan Capital led the round, ... including Acorn Campus Ventures, Suma Venture and Harbinger Venture ... and development of fully-human antibodies engineered to mimic the ...
Breaking Biology News(10 mins):Study helps assess impact of temperature on belowground soil decomposition 2Insects' fear limits boost from climate change, Dartmouth study shows 2
... SAN DIEGO, Calif. (March 10, 2009)Attempts to treat ... patients with below-the-knee angioplasty are still thwarted by ... site of angioplasty or stenting), the need for ... disease, leading to tissue death (gangrene) and amputation. ...
... SAN DIEGO, Calif. (March 10, 2009)The use of common ... (ABI)along with traditional risk scoring systemssuch as the Framingham ... in thousands of individuals who are not originally thought ... say researchers at the Society of Interventional Radiology,s 34th ...
... March 9 Explorations Group Inc. (OTC Bulletin ... letter of intent to acquire Daniel R. Smith & Associates, ... total of $4.2 million to be paid in a combination ... Intent, EXGI President David Coriaty stated "the acquisition of DRSA ...
Cached Biology News:Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3Simple test helps predict heart attack risk 2Simple test helps predict heart attack risk 3Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company 2
...
Contains L-glutamine...
... 140kDa GenBank Accession ... amino acids 926-941 (DKKVKPPFIPTIRGRE) of human PRK2. ... Quality Assurance Routinely evaluated by ... Stability 1 year at ...
...
Biology Products: